MedChemExpress Intelligence Profile

medchemexpress.comLast reviewed: October 20, 2026Research coverage: 86%

Overall data confidence:Unknown

Identity confidence

Moderate

6 of 10 identity fields independently documented

Corporate continuity

Continuity supported — domain registered 2009-05-14; vendor site footer claims Copyright 2013-2026 MedChemExpress; site live today with a current catalog (200,000+ bioactive molecules claimed), current promotions, and dated 2026 scientific-review content; third-party coverage spans 2017 (Prop 65 notice period) through 2026.

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

6 of 7 testing fields documented

Transaction transparency

High

5 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 86%. Our research on MedChemExpress remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Entity status researched (entity_status)
Public summary reviewed

Overview#

MedChemExpress is a large, long-running research-chemical catalog company operating at medchemexpress.com (domain registered 2009-05-14) and headquartered at 1 Deer Park Dr, Monmouth Junction, NJ 08852, selling bioactive compounds — including a substantial peptide catalog (vendor copy cites 7,000-8,000+ peptide products, MS/HPLC-validated) and custom peptide synthesis — to research buyers on research-use-only terms ('We do not sell to patients'). FIT: passes the peptide fit gate as a catalog + custom-synthesis seller. Identity: the U.S. operator is MedChemExpress LLC, a New Jersey LLC per a federal court filing, with Shanghai Haoyuan Chemexpress Co., Ltd. named alongside it in court and Prop 65 sources (a complaint alleges, on information and belief, a subsidiary relationship and a U.S. DMF-agent role — recorded as alleged, not verified); NJ DORES standing, formation date, principals, and registered agent were not retrieved and remain Unknown. Regulatory: all defined FDA searches (warning letters, recalls, import alerts) and the FTC search returned No Record Found; a California Prop 65 Notice of Violation (2020-00410, Tier 1 AG filing) alleges missing warnings since 2017. Litigation: Janssen/Pharma Mar trabectedin patent cases ended in a February 2026 consent judgment and permanent injunction against the NDA 219617 product (D.N.J. 2:25-cv-01867) — civil patent relief, no damages disclosed, no criminal proceedings. Testing: extensive in-house QC (NMR/HPLC/LC-MS, ISO 9001:2015/ISO 17025-referenced QMS, batch traceability, per-product COAs delivered with shipment) with no independent laboratory named and no public COA verification portal — the gap is independence/verifiability, not absence of testing claims. Commercial terms are published and conventional for the sector: 30-day Satisfaction Guarantee returns with prior authorization, 24-hour in-stock dispatch, published FedEx reference rates, Net 30 / Purchase Order ordering. No High/Critical safety or impersonation findings against this vendor; the vendor itself warns that third parties impersonate it.

Company Identity#

Vendor Brand NameMedChemExpress

HighSource: MedChemExpress homepage

Primary Website Domainmedchemexpress.com

ModerateSource: MedChemExpress — official website (intake domain confirmation)

Legal Entity NameMedChemExpress LLC

HighSource: California Attorney General (oag.ca.gov) — Proposition 65 Notice of Violation 2020-00410 naming MedChemExpress LLC

State of RegistrationNew Jersey

HighSource: Janssen v. EVER Valinject et al., N.D. Ill. No. 1:24-cv-07319 — Complaint, paragraph 9 (New Jersey LLC; 1 Deerpark Dr. Ste. Q, Monmouth Junction, NJ 08852)

Entity StatusNot independently verified

UnknownSource: NJ Division of Revenue & Enterprise Services — Business Entity Name Search

Incorporation / Formation DateNot independently verified

UnknownSource: Prospeo — MedChemExpress profile (Founded: 2009; headquarters address and phone)

Named Principals / ManagersNot independently verified

UnknownSource: MedChemExpress — About Us / Headquarters pages searched; no principal named

Registered AgentNot independently verified

UnknownSource: NJ Division of Revenue & Enterprise Services — Business Entity Name Search

Operating Address1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA

HighSource: MedChemExpress — Headquarters page (1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852; Tel 609-228-6898)

Address ConsistencyConsistent on building and town, with a suite-letter change over time — 1 Deer Park Dr, Monmouth Junction, NJ 08852 throughout; Suite Q in 2024-era sources (federal complaint; vendor brochure; third-party profiles) and Suite F on the vendor's current Headquarters page and in a 2026 supplier interview. No conflicting town, street, or ZIP in any source found.

ModerateSource: MedChemExpress — Headquarters page (Suite F, current)

Domain and Digital Identity#

Domain Registration Date2009-05-14

HighSource: Verisign RDAP — medchemexpress.com (registration 2009-05-14T11:35:57Z)

Domain Ownership / Registrar Change HistoryPartially known — current registrar Cloudflare, Inc.; RDAP record last changed 2021-01-04. Earlier registrar/ownership history not established in this pass; registrant identity is not disclosed in RDAP.

LowSource: Verisign RDAP — medchemexpress.com

Website ContinuityContinuity supported — domain registered 2009-05-14; vendor site footer claims Copyright 2013-2026 MedChemExpress; site live today with a current catalog (200,000+ bioactive molecules claimed), current promotions, and dated 2026 scientific-review content; third-party coverage spans 2017 (Prop 65 notice period) through 2026.

ModerateSource: Verisign RDAP — medchemexpress.com

Contact Channel IntegrityPublished channels are consistent across the site: Tel 609-228-6898, Fax 609-228-5909, sales email sales@medchemexpress.com and technical support tech@medchemexpress.com appear in the footer, Headquarters, Ordering Information, and Shipping pages with no conflicting numbers or addresses. The site also carries a banner warning that fraudsters may impersonate MedChemExpress on social media/messaging platforms and directing users to verify representatives and payment instructions through MedChemExpress.com — recorded as the vendor's own anti-fraud notice, not as a finding against the vendor.

HighSource: MedChemExpress — Headquarters page (Tel/Fax/email block)

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of fda.gov warning letters — no letter naming MedChemExpress

FDA Recall / Safety Action HistoryNo Record Found in the defined search

ModerateSource: Defined web search — MedChemExpress FDA recall

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search — MedChemExpress FDA import alert / detained

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of ftc.gov — no action naming MedChemExpress

State Regulatory / Attorney General ActionsCalifornia Proposition 65 Notice of Violation (Notice No. 2020-00410) naming MedChemExpress LLC, MedChemExpress USA, and Shanghai Haoyuan Chemexpress Co., Ltd. The notice, filed with the California Attorney General under Health and Safety Code section 25249.6, alleges failure to provide Prop 65 warnings for products sold via medchemexpress.com whose primary component is a chemical listed as causing cancer or reproductive harm, with exposure alleged since at latest February 19, 2017 through academic-laboratory use. Recorded as a Prop 65 60-day notice filed with the AG — it is not, on the document read, an AG-filed enforcement judgment. No other state AG or state-regulator action naming the vendor surfaced in the defined search.

ModerateSource: California Attorney General (oag.ca.gov) — Proposition 65 Notice of Violation 2020-00410 (MedChemExpress LLC et al.)

Relevant Civil LitigationJanssen Products, L.P. / Pharma Mar, S.A. trabectedin (Yondelis) patent litigation. (1) N.D. Ill. No. 1:24-cv-07319, filed 2024-08-15, naming Medchemexpress LLC among defendants (with EVER Valinject, Nexus Pharmaceuticals, Shanghai Haoyuan Chemexpress, and Ruyuan HEC Pharm) over a proposed trabectedin product referencing NDA No. 219617 and DMFs 36724/36899, for which the complaint alleges Medchemexpress is the authorized U.S. agent. (2) D.N.J. No. 2:25-cv-01867 — Consent Judgment and Permanent Injunction entered February 20, 2026: MedChemExpress admitted validity/enforceability of U.S. Patents 8,895,557 and 7,420,051 as to the NDA 219617 product and is permanently enjoined from making, using, offering for sale, selling in the U.S., or importing that product until expiration of the 557 Patent (including extensions/adjustments and pediatric exclusivity); claims dismissed with prejudice; no damages disclosed; each side bore its own fees. This is civil patent (ANDA/505(b)(2)) litigation, not a product-safety or deceptive-marketing case.

ModerateSource: Janssen v. EVER Valinject et al., N.D. Ill. No. 1:24-cv-07319 — Complaint (filed 2024-08-15)

Criminal / Injunctive ProceedingsNo criminal proceedings found in the defined search. Injunctive relief exists only as part of the civil patent case above: a permanent injunction by consent in D.N.J. No. 2:25-cv-01867 (February 2026) barring the NDA 219617 trabectedin product until patent expiry. No indictment, criminal charge, or government injunction naming MedChemExpress surfaced.

ModerateSource: Defined web search — MedChemExpress criminal / indicted / government injunction

Testing and COA Evidence#

Public COA AvailabilityCertificates of Analysis are provided per product — the vendor's Quality Management System page lists Certificate of Analysis (COA), Safety Data Sheet, product data sheet, and chemical analysis report among its pre-sale/customer quality services; the vendor's compound-handling guidance states product data sheets and QA documents (including the COA, which carries storage conditions) are emailed after shipment and can also be downloaded from the product webpage or requested from customer service. Custom peptides default to an analysis report including HPLC, MS and COA. COAs are therefore available to buyers per product/order rather than posted in a single public COA library.

ModerateSource: MedChemExpress — Quality Management System (COA/SDS/data-sheet quality services; batch management and traceability)

Batch / Lot SpecificityEstablished at the system level — the vendor's Quality Management System page describes warehousing and batch management, batch management and traceability, and product testing and release controls; the Easy Return page states products undergo full QC analysis (NMR, LC-MS, HPLC, Chiral HPLC). Individual COA documents were not sampled in this pass to confirm a printed batch/lot number on each certificate.

ModerateSource: MedChemExpress — Quality Management System (batch management and traceability)

Independent Laboratory IdentityNot independently verified

UnknownSource: MedChemExpress — Quality Management System (MCE Quality Analysis Platform; ISO 9001:2015 / ISO 17025 / cGMP)

COA Verification StatusNot verifiable through a public portal in this pass — no COA lookup/verification mechanism was found on medchemexpress.com; COAs are delivered with/after shipment and downloadable from the product webpage per the vendor's guidance, but cannot be authenticated against an issuing external lab online (testing is in-house).

ModerateSource: MedChemExpress — Quality Management System

Test RecencyCurrent-catalog testing is represented as ongoing — COAs/QA files are issued per shipment and the QMS page describes continuous product testing and release, batch monitoring, and nonconformance management. No dated, independently inspected COA was located in this pass, so no specific most-recent test date is recorded.

LowSource: MedChemExpress — Quality Management System (product testing and release; quality monitoring)

Testing CoverageVendor-stated coverage is catalog-wide: the About/QMS pages claim multi-level QC across a 200,000+ molecule portfolio with NMR, HPLC, LC-MS, IR and elemental analysis; the Easy Return page states chemicals are typically >98% purity by HPLC with verified bioactivity; peptide materials specifically are described as MS- and HPLC-validated (7,000+ peptides in vendor brochure copy; 8,000+ peptide products in current promotional copy), with unlimited custom peptide synthesis. Independent confirmation of coverage breadth was not found in this pass.

ModerateSource: MedChemExpress — Easy Return (full QC: NMR, LC-MS, HPLC, Chiral HPLC; typically >98% by HPLC)

Evidence ConsistencyClaims are internally consistent across the current site (research-use-only, 'We do not sell to patients', in-house NMR/HPLC/LC-MS QC, per-product COAs, ISO-referenced QMS). Two notes: (1) the headquarters suite letter differs by era (Suite Q in 2024 sources, Suite F currently) at the same building — a move within the building or a correction, not a conflicting address; (2) headcount/revenue figures in third-party profiles conflict widely (47 to 1,000+ employees; $7.5M to $75M revenue) and are not relied on. No falsified-testing-evidence indicators were found; testing is in-house, so the verification gap is independence, not contradiction.

ModerateSource: MedChemExpress — About Us

Payment, Refund and Shipping#

Accepted Payment MethodsPartially known — the Ordering Information page provides for ordering online, by phone/fax, and by Purchase Order emailed/faxed to the vendor, with payment due 30 days from invoice date (Net 30), 15% per annum interest on overdue payments, and the customer bearing wire-transfer/bank charges — which establishes Purchase Orders and wire/bank transfer as contemplated methods. No public list of accepted card brands, PayPal, or other checkout payment methods was found on the pages fetched, and the checkout flow cannot be inspected via text fetch.

LowSource: MedChemExpress — Ordering Information (Purchase Orders; Net 30; wire-transfer fees)

Refund / Return PolicySatisfaction Guarantee return policy: a customer who is not satisfied may return or exchange any item within 30 days after receiving the products, after first contacting Customer Service (sales@medchemexpress.com) to obtain a Return/Exchange Authorization; items returned without prior authorization may not be accepted, and returned items should be in the original packaging and in the same condition as originally purchased.

HighSource: MedChemExpress — Easy Return (Satisfaction Guarantee; 30 days; authorization required)

Shipping & Fulfillment RepresentationsIn-stock products are processed for shipping within 24 hours; out-of-stock items are replenished as soon as possible with direct customer updates. Shipments go via FedEx/DHL (small orders) — U.S. temperature-sensitive orders ship FedEx Priority Overnight or UPS Next Day Air rather than Ground. Published reference charges when no FedEx account is provided (free samples/small orders from the U.S.): $35 continental U.S., $50 for Alaska/Hawaii/Puerto Rico/Canada, $85 for other countries (€35 from the European warehouse); dry-ice shipments cost more per domestic logistics policy; severe weather may delay delivery.

HighSource: MedChemExpress — Shipping Rates & Policies

Terms / Policy StabilityCore commercial pages (Terms & Conditions of Sale, Shipping Rates & Policies, Easy Return, Ordering Information, Privacy and Cookie Policy) are live and mutually consistent in this pass; the Terms state MedChemExpress.com may amend the Terms at any time by posting the amended version, and that prices and product specifications may change without prior notice. No dated prior version was retrieved for a diff in this intake pass — future refresh cycles can diff policy pages directly.

ModerateSource: MedChemExpress — Terms & Conditions of Sale (amendment-by-posting; prices subject to change)

Customer Complaint PatternNo Record Found in the defined search

ModerateSource: Defined searches — BBB, Trustpilot, web (no profile or pattern found for MedChemExpress LLC)

Material Changes#

No material changes recorded.

Sources#

California Attorney General (oag.ca.gov) — Proposition 65 Notice of Violation 2020-00410 naming MedChemExpress LLCTier 1 · AuthoritativeState Regulatory NoticeAuthoritative

Retrieved: October 20, 2026